News & Updates
Filter by Specialty:
![T-Dxd improves PFS vs T-DM1 in second-line HER2-positive mBC treatment](https://sitmspst.blob.core.windows.net/images/articles/shutterstock-1800001342-39f2ac18-e132-4dab-88a3-b2683642c80c-square.jpg)
T-Dxd improves PFS vs T-DM1 in second-line HER2-positive mBC treatment
21 Sep 2021
byChristina Lau
Trastuzumab deruxtecan (T-Dxd) provides a highly clinically meaningful and statistically significant improvement in progression-free survival (PFS) vs trastuzumab emtansine (T-DM1) in second-line treatment of HER2-positive metastatic breast cancer (mBC), results of the phase III DESTINY-Breast03 trial have shown.